AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04073381 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Prehabilitation Program
Description: This is a 4 week prehabilitation program which uses both exercise and nutrition. Exercise will be prescribed at least 6 days a week. Three days a week , for 45 mins, participants will be asked to perform body, leg and arm exercises against light resistance while wearing pneumatic blood flow restriction arm and leg bands. minutes. On the alternate days participants will walk approximately 15 minutes while wearing the leg bands that restrict blood flow. Additionally, a nutrition supplement cocktail will be provided and should be taken every day within 1 hour after completing each exercise session. The 4 Week Nutrition (Sports Drink) Supplement Cocktail: will include whey protein (25 g/day), creatine monohydrate (8 g/day), and L-citrulline (5 g/day). The supplement mixture will be provided in daily packages by the investigators (nutrition supplements are not regulated by the FDA)
Study NCT05252039 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goals in Focus
Description: Goals in Focus (GiF) is a symptom-specific treatment program that targets motivational negative symptoms in patients with schizophrenia-spectrum disorders.~The aim is to improve setting and pursuit of personal relevant goals.~GiF follows a 24-individual-sessions treatment manual. GiF includes five treatment phases: 1) Preparation, 2) Goal-setting, 3) Goal-pursuit, and 4) Reflection and preparation of autonomous goal-pursuit. The interventions include generating positive goals, behavioral activation, training of anticipatory pleasure, challenging demotivating beliefs, training of problem-solving skills and social skills training.
Study NCT00275951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab Plus P-HDFL
Description: Cetuximab 400 mg/m2, IV, day 1 of cycle 1; then weekly IV 250 mg/m2. Cisplatin 24-hour IV infusion 35 mg/m2/day, plus HDFL (5-FU 2,000 mg/m2 and leucovorin 300 mg/m2), day 1 and day 8. HDFL IV, day 15.
Study NCT03402438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulacimstat (BAY1142524)
Description: single oral dose of 25 mg immediate-release tablet BAY1142524
Study NCT01449526 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: B&L Investigational Contact Lens
Description: Lenses will be worn on a daily wear basis for 3 months, new lenses dispensed monthly.
Study NCT01449526 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: B&L PureVision Contact Lens
Description: Lenses will be worn on a daily wear basis for 3 months, new lenses dispensed monthly.
Study NCT01575184 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: caudo-ipsilateral traction of shoulder
Description: After the head rotation (0, 40, 80 degrees) to the contralateral side from the ultrasound measuring site, the slight caudo-ipsilateral traction of shoulder will be applied without changing the degree of the head rotation.
Study NCT01575184 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The ultrasonographic measurements without shoulder traction
Description: After the head rotation (0, 40, 80 degrees) to the contralateral side from the ultrasound measuring site, the no traction of shoulder will be applied.
Study NCT04278521 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Transcranial Magnetic Stimulation
Description: Transcranial magnetic stimulation uses a rapidly changing magnetic field to induce current in brain tissue non-invasively. It is common procedure in both clinical and research settings, and it has well established guidelines for safe an ethical use which maximize safety for all subjects.
Study NCT01500642 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Slit One
Description: slit one sublingual immunotherapy 200 stu
Study NCT01500642 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Slit One
Description: slit one vestibular immunotherapy 200 stu
Study NCT01500642 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Slit One ragweed
Description: slit one 400 stu dose ragweed (sublingual doubled immunotherapy)
Study NCT03073590 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Intervention factory with hot lunch
Description: A nutritionally enhanced lunch meal program (increased dietary diversity plus inclusion of multi-nutrient fortified rice), provision of once weekly iron/folate supplement to female workers, and a BCC program conducted in the factory setting focused on improving health and nutrition for women and children, with a focus on anemia prevention.The BCC program will be enhanced to include modules on nutrition (balanced diets/dietary diversity, iron/folate rich foods), infant and young child nutrition (IYCN), and an overview module on anemia prevention, hand-washing with soap and dietary diversity at the very beginning of the intervention.
Study NCT03073590 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Intervention factory without lunch program
Description: In a selected garment factory that does not have a lunch program, the intervention will consist of the twice weekly provision of iron/folate supplements to female workers, and the enhanced BCC program, as described above.
Study NCT03073590 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Control factory with lunch program
Description: One control factory who provides regular lunch meal and a nutrition and health behavior change communications (BCC) program.
Study NCT03073590 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control factory without lunch program
Description: One control factory was selected where only the standard Behavior change communication (BCC) was implemented.
Study NCT01794091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Description: Eplerenone 25 mg daily for 6 months
Study NCT01794091 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00615056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab (avastin)
Description: Bevacizumab intravenous \[IV\] infusion 5 mg/kg every two weeks until disease progression, intolerance or withdrawal of consent.
Study NCT00615056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU])
Description: Irinotecan (180 mg/m²) intravenous infusion \[IV\] over 90 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed immediately by 5-FU bolus (400 mg/m²) intravenous \[IV\] and a subsequent 5-FU infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
Study NCT00615056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736 (axitinib)
Description: Axitinib is given at a starting dose of 5 mg twice daily \[BID\] continuous dosing until disease progression, intolerance or withdrawal of consent.
Study NCT00615056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])
Description: Oxaliplatin (85 mg/m²) intravenous infusion \[IV\] over 120 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed by 5-FU IV bolus (400 mg/m²) and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
Study NCT00615056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI (irinotecan, leucovorin, 5-fluorouracil [5FU])
Description: Irinotecan (180 mg/m²) intravenous infusion \[IV\] over 90 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed immediately by 5-FU bolus (400 mg/m²) IV and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
Study NCT00615056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab (avastin)
Description: Bevacizumab intravenous infusion \[IV\] 5 mg/kg every two weeks until disease progression, intolerance or withdrawal of consent.
Study NCT00615056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])
Description: Oxaliplatin (85 mg/m²) IV infusion over 120 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed by 5-FU IV bolus (400 mg/m²) and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
Study NCT01894269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.
Description: In experimental group, Lamivudine 100mg once daily; or Entecavir 0.5mg once daily will be commenced after TACE.
Study NCT02187588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eschscholtzia Californica - low dose
Study NCT02187588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eschscholtzia Californica - high dose
Study NCT02187588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Study NCT02187588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eschscholtzia Californica - low dose Placebo
Study NCT02187588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eschscholtzia Californica - high dose Placebo
Study NCT02187588 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Eschscholtzia Californica - high dose Placebo
Study NCT02187588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen Placebo
Study NCT02187588 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen Placebo
Study NCT01542216 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition and Exercise Group
Description: Patients randomized to this arm will receive nutrition and exercise consultations. Exercise consultations will home- and institution-based.
Study NCT01542216 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Yoga and Stretching Group
Description: Patients randomized to this arm will receive consultations on yoga and stretching exercises.
Study NCT04645303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone acetonide 10mg/ml
Description: A1-Pulley infiltration for trigger finger
Study NCT02936401 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBSR
Description: Mindfulness Based Stress Reduction (MBSR) is a standardized 8 week course taught by trained instructors.
Study NCT02110316 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dosage form of voriconazole
Description: Instead of an oral dose of voriconazole, patients receive one intravenous dose of voriconazole (in the same dose as the oral dose).
Study NCT04384302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual training
Description: Pre-defined visual training protocol including the optometrical unit exercises
Study NCT02922270 — intervention group
Intervention type: OTHER
Intervention: Peritoneal dialysis patients at the Istanbul Medical Faculty
Description: The aims of this study were to evaluate patient and technique survival rates, investigate peritonitis rates and evaluate factors affecting mortality in peritoneal dialysis (PD) patients over a period of 20 years at Istanbul Faculty of Medicine Peritoneal Dialysis Unit.
Study NCT05410470 — intervention group
Intervention type: DRUG
Intervention: Ruxolitinib
Study NCT04130295 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wearable intensive nerve stimulator
Description: The wearable device consists of 2 leads that provide biphasic, with alternating lead phase, asymmetrical rectangular current at a pulse duration of 0.28 msec, a randomly varying pulse frequency between 60-100 Hz, with a maximum intensity of 100mA.
Study NCT02933177 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2 months control condition - 4 months chariot-flash
Description: The control condition is to propose the usual procedures for the management of productive symptoms during the emergence or increase of these symptoms.~The chariot-flash condition is a chariot with eleven drawers. Each drawer contains an activity (lasting about 15 minutes):~* Boards of known photographs to recall autobiographical memories~* Newspapers to read, talk, associate memories around an article~* Massage Oil, refreshing wipes, cream to reconnect with the body~* Clay, cookie pieces, washable felt and paper to create shapes, draw.~* Walk with a person of the healthcare team the case of behavioral disorders in type of ambulation and untimely exit .~* Listening to music~* Relaxation-Breathing~* Cushion, foam balls to vent his energy on secure hardware.~* Plush doll or to invest a vector object of affection and empathy~* Sensory flash balls that the patient can squeeze, throw, roll.~* Games with which the patient can play according to its possibilities.
Study NCT02933177 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4 months control condition-2 months chariot flash
Description: The control condition is to propose the usual procedures for the management of productive symptoms during the emergence or increase of these symptoms.~The chariot-flash condition is a chariot with eleven drawers. Each drawer contains an activity (lasting about 15 minutes):~* Boards of known photographs to recall autobiographical memories~* Newspapers to read, talk, associate memories around an article~* Massage Oil, refreshing wipes, cream to reconnect with the body~* Clay, cookie pieces, washable felt and paper to create shapes, draw.~* Walk with a person of the healthcare team the case of behavioral disorders in type of ambulation and untimely exit .~* Listening to music~* Relaxation-Breathing~* Cushion, foam balls to vent his energy on secure hardware.~* Plush doll or to invest a vector object of affection and empathy~* Sensory flash balls that the patient can squeeze, throw, roll.~* Games with which the patient can play according to its possibilities.
Study NCT05504629 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent training order 1
Description: atag
Study NCT05504629 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RT+ET
Description: aetaer
Study NCT00244712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: emtricitabine/tenofovir
Description: The intervention is an active comparator regimen containing tenofovir/emtricitabine + abacavir/lamivudine placebo + lopinavir/ritonavir.
Study NCT00244712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abacavir/lamivudine
Description: The experimental intervention is a regimen containing abacavir/lamivudine + tenofovir/emtricitabine placebo + lopinavir/ritonavir.
Study NCT00624806 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily telephone calls
Description: Patients randomized to this group receive daily phone calls to remind them what they should do to prevent ulcers.
Study NCT00624806 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weekly telephone calls
Description: Patients randomized to this group receive weekly phone calls to remind them what they should do to prevent ulcers.
Study NCT03639649 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: STHLM3
Study NCT03639649 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: STHLM3
Study NCT02419118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Treatment of myeloma patients with Daratumumab
Study NCT02419118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Treatment of myeloma patients
Study NCT02090478 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low sugar diet
Description: All subjects followed their usual diet during month 1. For months 2-4: sham diet intervention for the control group, 40% reduction in sugar calories for the experimental group. All subjects were allowed to chose any diet they wished during month 5.
Study NCT02090478 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham diet manipulation
Description: Subjects in the control group will meet with a dietician and discuss diet records, but the dietician will not instruct the control subjects to reduce the number of calories from simple sugars in the diet
Study NCT03694145 — intervention group
Intervention type: OTHER
Intervention: In-Person Eye Examination
Description: Dilated in-person eye examination by a board-certified ophthalmologist or retinal fellow.
Study NCT01115205 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised walking
Description: Walk training, 3 sessions per week for 4 months, under the supervision of a qualified personal trainer.
Study NCT01115205 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard counselling procedure
Description: Verbal and written information about the benefits of exercise and instructions aimed to encourage physical activity. In addition, one group session of counselling on these issues.
Study NCT03606265 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: App+Web
Description: Patients will use an app daily twice and physicians will use a website to consult the characteristics of the alarms the app will send them in the presence of an unwanted event
Study NCT03606265 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Patients will be offered the usual treatment for their pain, which is not changed by study participation
Study NCT00441168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adriamycin
Description: adriamycin: 9mg/m² intravenous (IV) push on days 1 to 4
Study NCT00441168 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adriamycin
Description: adriamycin: 9mg/m² intravenous (IV) push on days 1 to 4
Study NCT00441168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: bortezomib: 1.3 mg/m² intravenous (IV) bolus on days 1, 4, 8, and 11
Study NCT03938506 — intervention group
Intervention type: OTHER
Intervention: cuff pressure of the endotracheal tube
Description: The endotracheal intubation will be performed after the anesthetic induction. The cuff will be inflated using the air by the palpation method. The cuff pressure of the endotracheal tube will be measured using the manometer.
Study NCT04016259 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cranial Electrical Stimulation (CES)
Description: CES will be applied for 60 minutes per session daily for 2 weeks (Monday to Friday) via the Alpha-Stim M Electromedical Products International, Inc., Mineral Wells, TX).
Study NCT04016259 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham-CES
Description: For sham CES, the electrodes will be identical look and be placed in the same positions as for active stimulation, but the stimulator will not deliver electrical current.
Study NCT03160885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Description: Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration
Study NCT03160885 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains the same excipients, in the same concentration only lacking tralokinumab
Study NCT03160885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo contains the same excipients, in the same concentration only lacking tralokinumab
Study NCT01105156 — intervention group
Intervention type: BEHAVIORAL
Intervention: VEW Questionnaire
Description: Patient Self reported questionnaire filled in.
Study NCT02419118 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Treatment of myeloma patients
Study NCT02419118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Treatment of myeloma patients
Study NCT02419118 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Treatment of myeloma patients
Study NCT02578173 — intervention group
Intervention type: DEVICE
Intervention: AVERT PLUS
Study NCT00644436 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tetrix
Description: single topical application
Study NCT00644436 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tetrix
Description: Single topical application
Study NCT01232985 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RD047-26
Description: RD047-26 emollient gel
Study NCT02915978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl delivered via sublingual spray
Study NCT02915978 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo delivered via sublingual spray
Study NCT03077204 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 1 or 2-Level ACDF utilizing BIO4 with Bio AVS Cervical Allograft (with graft window).
Description: The study will utilize the BIO4 on label as a 361 HCT/P (human cell, tissue and cellular and tissue-based product) for homologous use for the repair, replacement or reconstruction of bone defects. Interbody fusion (1 or 2-level fusion) in conjunction with an allograft (hct/p) interbody spacer (anterior approach in the cervical spine with hardware). Investigators will also use the Aviator Anterior Cervical Plating System for anterior intervertebral screw fixation of the cervical spine at levels C2-T1. The Aviator Anterior Cervical Plating System is intended for use as an aid in cervical spinal fusion and is intended for unilateral fixation. The Aviator plates are intended to be used with the Aviator bone screws.